Recursion and Exscientia, two pioneers in artificial intelligence (AI)-based drug development, have completed a business combination that they vowed will enhance their ability to carry out drug ...
Investing.com - Recursion Pharmaceuticals (NASDAQ: RXRX) reported fourth quarter EPS of $-0.42, $0.04 better than the analyst ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results